相关实验视频

Updated: May 5, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

大脑的定量敏感性映射与阿尔茨海默病相关区域的炎症变化有关

Seyyed Ali Hosseini^1,2,3, Stijn Servaes^1,2,3, Arthur C Macedo^1,2,3

¹Translational Neuroimaging Laboratory, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

|February 9, 2026

概括

定量敏感性映射 (QSM) 显示阿尔茨海默病 (AD) 大脑组织中偏磁性物质增加,反映了炎症而不是蛋白质积累. 这种MRI技术为AD治疗开发提供了新的见解.

科学领域:

神经成像是一种神经成像.
生物标志物生物标志物
阿尔茨海默氏症疾病研究研究

背景情况:

大脑组织中对磁性物质的积累与阿尔茨海默病 (AD) 和炎症有关.
定量敏感度映射 (QSM) 测量了对磁负荷的测量,可能作为AD的指标.
QSM,AD病理 (甲胺β和) 和炎症之间的关系需要进一步调查.

研究的目的:

评估QSM之间的关联,作为对磁负荷的衡量标准,以及大脑Aβ和tau聚合物.
评估QSM与血和脑脊液 (CSF) 中的炎症生物标志物的相关性.
在整个AD频谱的个体中调查QSM的纵向变化.

主要方法:

利用MRI定量敏感度映射 (QSM) 和T1加权扫描,对TRIAD队列中的315名参与者进行了扫描.
在基线和12个月和24个月的随访期间评估的平均皮层和皮层下敏感度值.
与AD相关的血和CSF炎症生物标志物以及Aβ和tau水平相关的QSM值.

主要成果:

在基线时,阿兹海默症患者在特定的大脑区域 (后侧环状皮质,前皮质,基底) 的QSM显著高于对照人群.
在24个月内,QSM在前带带肌 (MCI) 和皮和海马体 (痴呆症) 中增加.
QSM与几个免疫生物标志物 (IL-10RB,PD-L1,SCF,TWEAK,CSF-1,CXCL9,HGF,CD40) 相相关,但与Aβ或tau生物标志物没有相关.

结论:

在阿尔茨海默病中,QSM反映了组织炎症,而不是蛋白质聚合.
通过QSM测量的组织敏感性负载的大小可以了解大脑功能障碍.
QSM显示出作为监测疾病进展和开发AD治疗方法的有价值工具的潜力.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在QSM中,QSM是QSM.大脑的敏感性.免疫生物标志物免疫生物标志物神经炎症是一种神经炎症.

更多相关视频

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Published on: January 9, 2020

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...